CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration has approved a new drug for the treatment of chronic hepatitis B, the drug's manufacturer said Wednesday. The drug, entecavir, is taken orally and is designed to work by preventing the virus that causes the illness from reproducing. The chronic form of hepatitis B can permanently damage the liver and lead to cirrhosis and liver cancer. Entecavir is made by Bristol-Myers Squibb and will be sold under the trade name Baraclude. The company said it could be available in early April. Current treatment options for chronic hepatitis include interferon, given by injection, and two drugs administered orally, lamivudine and adefovir dipivoxil. In clinical trials the main side effects reported for the new drug were headache, tiredness, dizziness, and nausea. The Hepatitis B Foundation estimates that 1.2 million Americans have hepatitis B and another 100,000 are infected annually. The hepatitis B virus can be transmitted through sexual activity, particularly through oral-anal contact. The Gay and Lesbian Medical Association urges all sexually active gay and bisexual men to be vaccinated against hepatitis A and B, but fewer than half of the nation's gay men have received the vaccines. (AP, with additional reporting by Advocate.com)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Advocate Channel
HealthAdvocate Channel
WomenMuslim Women Athletes Condemn Hijab Bans, Fight For Inclusive Clothing in Sports
January 17 2023 11:45 AM
Advocate Channel
Police